| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
TRACK to:
|
|
Electronic letters published:
![[Read Comment]](/icons/misc/sectionDOWN.gif){kind=icon}
Re: Sliding Scale Insulin: Questioning a Therapeutic Tradition
Re: Diabetes Care Sub-Optimal
Diabetes Care Sub-Optimal
sliding scale
Re: Fine points regarding Sliding Scale Insulin
Sliding Scale Insulin: Questioning a Therapeutic Tradition
Fine points regarding Sliding Scale Insulin
|
|
|||
|
charlene m devito, harrison,usa RN,CDE north arkansas regional med. ctr
Send response to journal:
|
As a diabetes educator in a small hospital (150 beds) I have been asked by my supervisor to come up with a protocol for sliding scale insulin use.....I have been told by many endocrinologists that "sliding scales are of no use, they are trying to fix what has already happened, etc. etc.....". Our physicians have also heard this from various cme's but continue to write sliding scale orders, some with no rhyme or reason, and then to send the pt. home on same. I don't know where to begin to convince them there are better ways to "supplement" the pt. needs yet, I still see them "hold" insulin orders on type 1 pts. who are going to surgery or having procedures then the nurses play "catch-up" the rest of the day...help!!! Competing interests: None declared |
|||
|
|
|||
|
Lori M. Dickerson, Charleston, SC USA Medical University of South Carolina
Send response to journal:
|
Thank you for your interest in our manuscript. You are completely correct - our study supported the lack of efficacy of the sliding scale of insulin in the hospitalized diabetic patient admitted for a comorbid condition, as was our hypothesis. Poor glycemic control in this population and setting is common, but it is unknown if improved short-term glycemic control during hospitalization results in improved outcomes in this group. The definition of 300 mg/dL was chosen based on the ADA definition of hyperglycemia at the time of study development, and was considered a clinically important value beyond which most clinicians would make an intervention. A clinical trial is needed to determine if short-term glycemic control can be improved using long or intermediate acting insulin used in this population and setting. Competing interests: None declared |
|||
|
|
|||
|
Karen M. Green, Elmhurst, USA Diabetes Nurse Practitioner
Send response to journal:
|
The article simply demonstrated the need for better diabetes care in the hospital. Of the type 2 diabetes patients studied one out of three had hyperglycemia. This just proves there needs to be long or intermediate acting insulin used in these patients. Your definition of hyperglycemia at 300mg/dl is not in line with the 200mg/dl used in other studies. The number of patients with hyperglycemia at 200mg/dl are probably considerably more in patients with and without sliding scale. Your article mearly supports the idea that the sliding scale is ineffective. Competing interests: None declared |
|||
|
|
|||
|
Mitchell Silverman, Physician Private Practice
Send response to journal:
|
This report flies in the face of my own personal experience. My interpretation of your findings is as follows: since this is unblindied, I would suspect that those in the sliding scale group tending to be more passive in thier adjustiments of standing insulin dosing, or even in the institution of standing onsulin in thoses on oral agents. The may have been attempted to overrely on the sliding scale. In contrast those in the no sliding scale arm were essentially forced to add or adjust the standing insulin since they had no alternative. We would all agree that a proper standing regimen is superior to a sliding scale. But your report does not convince me that adding a well thought out supplemental sliding scale in additon to an aggressive adjusted mutlidose basal/ bolus regimen does not enhance the response. Competing interests: None declared |
|||
|
|
|||
|
Lori M. Dickerson, Clinical Pharmacist Medical University of South Carolina
Send response to journal:
|
Dear Dr. Papreck: I hope our article has been helpful to your P&T committee and its decision making regarding this issue. When we wrote the grant, lispro wasn't used significantly in practice in the SSI regimen in any of our participating institutions, so we did not consider that option. Of course, practice has changed in that direction today, so the interpretation of our results should consider that difference. You are also correct that the SSI regimen "times" are not exactly according to our plan of q 6 hours, but more in tune with the hospital schedule/meal plan. As our overall goal was to mimic usual practice, we did not dictate the SSI times of administration, just the scale noted in the manuscript. Any of these issues could affect the rates of hypoglycemia (and I guess hyperglycemia too), but since our rates of hypoglycemia were low already, it's unlikely that these would change our results significantly. Sincerely, Lori M. Dickerson MUSC Family Medicine Competing interests: None declared |
|||
|
|
|||
|
Stephen J. Spann, Family Physician Department of Family and Community Medicine, Baylor College of MedicineS
Send response to journal:
|
The article by Dickerson et al reminds us that we continue to follow therapeutic traditions in our daily practices that have never been submitted to rigorous scientific evaluation. Despite our emphasis on evidence-based medical practice, many of our diagnostic and therapeutic interventions lack supporting scientific evidence. The authors are to be applauded for taking on this longstanding therapeutic tradition. Although this is not a "perfect" randomized clinical trial (convenience sample, lack of blinding of patients and clinicians), the study's findings are clinically believable. Although there is potential for patient selection bias and clinician measurement or reporting bias, I believe that these are unlikely in this multisite, clinical research study. It is important that this study be replicated using a consecutive patient sampling method and double-blinding. In the meantime, I will think twice before writing for sliding scale insulin in a hospitalized type 2 diabetic patient. Competing interests: None declared |
|||
|
|
|||
|
K. Thomas Papreck, MD, Physician Fitzgibbon Hospital Marshall, MO
Send response to journal:
|
Our hospital P&T committee has been looking for an article similar to that researched by Dickerson et. al. Two questions come to mind; had they considered using the newer lispro type insulins in the sliding scale regimen to perhaps lessen the incidence of hypoglycemia and what was the hourly interval usually used between meals and bedtime. We have found institutions that give SS insulin 5 hours apart during the day ( 0700,1200,1700 )but then give "bedtime" SS insulin at 2000hrs, only 3 hours later. Could the authors comment? Thanks! Competing interests: None declared |
|||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
TRACK: